Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NextCure, Inc. - Common Stock (NQ: NXTC )

0.7573 +0.0327 (+4.51%)
Streaming Delayed Price Updated: 3:59 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NextCure, Inc. - Common Stock

< Previous 1 2 Next >
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
From NextCure
Via GlobeNewswire
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences 
From NextCure
Via GlobeNewswire
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
From NextCure
Via GlobeNewswire
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From NextCure
Via GlobeNewswire
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
From NextCure
Via GlobeNewswire
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74 
From NextCure
Via GlobeNewswire
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
From NextCure
Via GlobeNewswire
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
From NextCure
Via GlobeNewswire
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
From NextCure
Via GlobeNewswire
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
From NextCure
Via GlobeNewswire
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
From NextCure
Via GlobeNewswire
NextCure Provides Year-End Clinical Pipeline Updates
From NextCure
Via GlobeNewswire
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
From NextCure
Via GlobeNewswire
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting 
From NextCure
Via GlobeNewswire
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
From NextCure
Via GlobeNewswire
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
From NextCure
Via GlobeNewswire
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
From NextCure
Via GlobeNewswire
Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease
From NextCure
Via GlobeNewswire
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From NextCure
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS